RxDoctor Payments Data

Bradley Waterman, MD

Urology · Salt Lake City, UTNPI 1699718809

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations.

$6,016in general payments, 2019–2025

Across 286 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$659
  • AbbVie$592
  • Ferring Pharmaceuticals Inc.$453
  • Astellas Pharma US Inc$388
  • Endo Pharmaceuticals Inc.$311
  • Boston Scientific$306
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,012100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,016 in reported general payments places this provider in the 65th percentile of 96 urology providers in Utah.

See all urology providers in Utah

Medicare billing

Part B allowed, 2024
$208,393
Medicare patients
493
Services billed
9,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron125$108,645
GemtesaVibegron82$79,869
ElmironPentosan Polysulfate Sodium14$13,463
Tamsulosin Hcl416$6,543
Potassium Citrate ErPotassium Citrate44$5,577
Methenamine Hippurate35$4,040
Testosterone Cypionate85$4,002
Solifenacin Succinate75$2,820
Tadalafil17$2,402
Finasteride173$2,140
Testosterone20$2,140
Dutasteride38$952
Oxybutynin Chloride ErOxybutynin Chloride35$844
Alfuzosin Hcl ErAlfuzosin Hcl33$753
NitrofurantoinNitrofurantoin Macrocrystal13$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$388$108,645125 claims
Sumitomo Pharma America, Inc.Gemtesa$245$79,86982 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 96 urology providers in Utah.

Other urology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →